Human GM-CSF antigen binding proteins
Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.
1. An isolated antigen binding protein that binds granulocyte macrophage colony stimulating factor (GM-CSF) comprising:
A) a CDRH1 of SEQ ID NO: 22, a CDRH2 of SEQ ID NO: 23 and a CDRH3 of SEQ ID NO: 24, and
B) a CDRL1 of SEQ ID NO:16, a CDRL2 of SEQ ID NO: 17, and a CDRL3 of SEQ ID NO: 18.
2. The isolated antigen binding protein of claim 1 wherein said antigen binding protein comprises a heavy chain variable region (VH) of SEQ ID NO: 21, and/or a light chain variable region (VL) SEQ ID NO: 15.
3. The isolated antigen binding protein of claim 1 , wherein said antigen binding protein is a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof.
4. The isolated antigen binding protein of claim 3 , wherein said antibody fragment is a Fab fragment, a Fab' fragment, a F(ab') 2 fragment, a Fv fragment, a diabody, or a single chain antibody molecule.
5. The isolated antigen binding protein of claim 3 , wherein said antigen binding protein is a human antibody.
6. The isolated antigen binding protein of claim 3 , wherein said antigen binding protein is a monoclonal antibody.
7. The isolated antigen binding protein of claim 3 wherein said antigen binding protein is of the IgG1-, IgG2 -, IgG3- or IgG4-type.
8. The isolated antigen binding protein of claim 7 , wherein said antigen binding protein is of the IgG1- or IgG2-type.
9. The isolated antigen binding protein of claim 1 , wherein said antigen binding protein is coupled to a labeling group.
10. The isolated antigen binding protein of claim 1 , wherein said antigen binding protein inhibits binding of GM-CSF to the extracellular portion of human GM-CSF.
11. A pharmaceutical composition comprising an antigen binding protein according to claim 1 , and pharmaceutically acceptable excipient.
12. The pharmaceutical composition of claim 11 , further comprises an additional active agent.
13. The pharmaceutical composition of claim 12 , wherein said additional active agent is selected from the group consisting of a radioisotope, radionuclide, a toxin, or a therapeutic and a chemotherapeutic group.